OtherPublished 8 Jul 2016
Personalized medicine in hepatocellular carcinoma: rationale and clinical data
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hepatocellular carcinoma (HCC) is the most common primary liver tumor. Its incidence is increasing in the West due to the expansion of hepatitis C virus infection and nonalcoholic fatty liver disease; globally the most important cause of HCC is chronic infection by hepatitis B virus. Due to the surveillance policy, HCC diagnosis at an early stage is increasing. Liver transplantation, hepatic resection, percutaneous ablation and transarterial chemoembolization have emerged as effective therapies with both curative and palliative intention. In 2008, a seminal paper was published in the New England Journal of Medicine in which Llovet and collaborators showed that sorafenib prolongs survival in the advanced stage of disease. This drug, an oral multikinase inhibitor, indicated the beginning of a new era in which the molecular classification of tumors and personalized treatments will be the main challenge.
Keywords
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Maria Pipa-Muniz”
- BylineArticles whose byline prints “Maria Varela”
- BylineArticles whose byline prints “Luisa Gonzalez-Dieguez”
- BylineArticles whose byline prints “Manuel Rodguez”